Chimerix to Present at TD Cowen 44th Annual Health Care Conference

Rhea-AI Summary

Chimerix (CMRX) CEO to participate in Targeted Oncology Panel at TD Cowen 44th Annual Health Care Conference. Audio webcast available on Chimerix's website.

DURHAM, N.C., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Andriole, Chief Executive Officer, will participate in a Targeted Oncology Panel at the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024 at 12:50 p.m. ET.

An audio webcast of the panel discussion will be available on the Investor Relations section of Chimerix's website at ir.chimerix.com, where it will be archived for approximately 90 days.

About Chimerix

Chimerix is a biopharmaceutical company with a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The Company’s most advanced clinical-stage development program, ONC201, is in development for H3 K27M-mutant glioma.

CONTACT:
        
Will O’Connor
Stern Investor Relations
212-362-1200
will@sternir.com

FAQ

When will Mike Andriole, CEO of Chimerix, participate in the Targeted Oncology Panel?

Mike Andriole, CEO of Chimerix, will participate in the Targeted Oncology Panel at the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024, at 12:50 p.m. ET.

Where can the audio webcast of the panel discussion be accessed?

The audio webcast of the panel discussion will be available on the Investor Relations section of Chimerix's website at ir.chimerix.com.

For how long will the audio webcast be archived?

The audio webcast of the panel discussion will be archived on Chimerix's website for approximately 90 days.